Organon & Co. (OGN)
NYSE: OGN · Pharmaceutical Preparations · Jersey City, NJ · filing with the SEC since 2020
Grade5.4
◀ Past 6.6● Present 5.9▶ Future 3.6
Income statement, as filed
In millions of US dollars (USD), as filed; per-share figures in US dollars; share counts in thousands. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Report filed | Feb 24, 2026 | Feb 28, 2025 | Feb 26, 2024 | Feb 27, 2023 | Mar 21, 2022 | · | · |
| Revenue | 6,216 | 6,403 | 6,263 | 6,174 | 6,304 | 6,532 | 7,777 |
| Cost of revenue | 2,903 | 2,688 | 2,515 | 2,294 | 2,382 | 2,119 | 2,274 |
| Gross profit | 3,313 | 3,715 | 3,748 | 3,880 | · | · | · |
| Research and development | 366 | 469 | 528 | 471 | 339 | 210 | 220 |
| Selling, general and administrative | 1,721 | 1,760 | 1,893 | 1,704 | 1,668 | 1,356 | 1,443 |
| Interest expense | 504 | 520 | 527 | 422 | 258 | 0 | 0 |
| Income before income taxes | 425 | 807 | 673 | 1,122 | 1,529 | 2,752 | 3,696 |
| Income tax expense | 238 | -57 | -350 | 205 | 178 | 496 | 390 |
| Income from continuing operations | · | · | 1,023 | 917 | 1,351 | 2,256 | 3,306 |
| Income from discontinued operations | · | · | 0 | 0 | 0 | -96 | -88 |
| Net income | 187 | 864 | 1,023 | 917 | 1,351 | 2,160 | 3,218 |
| Earnings per share, basic | 0.72 | 3.36 | 4.01 | 3.61 | 5.33 | 8.52 | 12.69 |
| Earnings per share, diluted | 0.72 | 3.33 | 3.99 | 3.59 | 5.31 | 8.52 | 12.69 |
| Weighted average shares, basic | 259,495 | 257,046 | 255,239 | 254,082 | 253,538r | 253,516 | 253,516 |
| Weighted average shares, diluted | 260,764 | 259,152 | 256,270 | 255,169 | 254,193r | 253,516 | 253,516 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfGoodsAndServicesSoldGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseInterest expense what its borrowing cost
us-gaap:InterestExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitIncome from continuing operations profit from the businesses it keeps
us-gaap:IncomeLossFromContinuingOperationsIncome from discontinued operations profit or loss from businesses it sold or closed
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntityNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding